Abstract #100: Comparison of Extended-Release Metformin and Immediate-release Metformin

2004 ◽  
Vol 10 ◽  
pp. 35
Author(s):  
Mark Kipnes ◽  
Robert M. Niecestro
Keyword(s):  
Extended Release ◽  
Immediate Release

scholarly journals Benznidazole Extended-Release Tablets for Improved Treatment of Chagas Disease: Preclinical Pharmacokinetic Study

2016 ◽  
Vol 60 (4) ◽  
pp. 2492-2498 ◽  
Author(s):  
Marcelo Gomes Davanço ◽  
Michel Leandro Campos ◽  
Talita Atanazio Rosa ◽  
Elias Carvalho Padilha ◽  
Alejandro Henao Alzate ◽  
...  
Keyword(s):  
Chagas Disease ◽  
Extended Release ◽  
Hydroxypropyl Methylcellulose ◽  
Immediate Release ◽  
Relative Bioavailability ◽  
Pharmacokinetic Parameters ◽  
Therapeutic Success ◽  
Preclinical Pharmacokinetics ◽  
Bioavailability Study

ABSTRACTBenznidazole (BNZ) is the first-line drug for the treatment of Chagas disease. The drug is available in the form of immediate-release tablets for 100-mg (adult) and 12.5-mg (pediatric) doses. The drug is administered two or three times daily for 60 days. The high frequency of daily administrations and the long period of treatment are factors that significantly contribute to the abandonment of therapy, affecting therapeutic success. Accordingly, this study aimed to evaluate the preclinical pharmacokinetics of BNZ administered as extended-release tablets (200-mg dose) formulated with different types of polymers (hydroxypropyl methylcellulose K4M and K100M), compared to the tablets currently available. The studies were conducted with rabbits, and BNZ quantification was performed in plasma and urine by ultraperformance liquid chromatography methods previously validated. The bioavailability of BNZ was adequate in the administration of extended-release tablets; however, with the administration of the pediatric tablet, the bioavailability was lower than with other tablets, which showed that the clinical use of this formulation should be monitored. The pharmacokinetic parameters demonstrated that the extended-release tablets prolonged drug release from the pharmaceutical matrix and provided an increase in the maintenance of the drug concentrationin vivo, which would allow the frequency of administration to be reduced. Thus, a relative bioavailability study in humans will be planned for implementation of a new product for the treatment of Chagas disease.

Steady-state pharmacokinetic profile of OROS hydromorphone extended release and hydromorphone immediate release

2010 ◽  
Vol 11 (4) ◽  
pp. S44
Author(s):  
K. Moore ◽  
D. St. Fleur ◽  
N. Marricco ◽  
T. Ariyawansa ◽  
V. Page ◽  
...  
Keyword(s):  
Steady State ◽  
Extended Release ◽  
Immediate Release ◽  
Pharmacokinetic Profile

Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages

2009 ◽  
Vol 87 (2-3) ◽  
pp. 256-259 ◽  
Author(s):  
Bernhard J. Steinhoff ◽  
Anne-Sophie Wendling
Keyword(s):  
Extended Release ◽  
Immediate Release ◽  
Short Term

scholarly journals PAR5 COST-EFFECTIVENESS OF EXTENDED-RELEASE AND IMMEDIATE-RELEASE TRAMADOL FOR THE TREATMENT OF CHRONIC OSTEOARTHRITIS PAIN

2007 ◽  
Vol 10 (3) ◽  
pp. A118 ◽  
Author(s):  
AD Patkar ◽  
P Langley ◽  
C Janagap ◽  
K Meyer ◽  
A Grogg ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Extended Release ◽  
Immediate Release ◽  
Osteoarthritis Pain

scholarly journals Comparative effects of immediate‐release and extended‐release aspirin on basal and bradykinin‐stimulated excretion of thromboxane and prostacyclin metabolites

2016 ◽  
Vol 4 (2) ◽  
Author(s):  
Jorge L. Gamboa ◽  
Jessica K. Devin ◽  
Claudia E. Ramirez ◽  
Chang Yu ◽  
Hui Nian ◽  
...  
Keyword(s):  
Extended Release ◽  
Immediate Release
Sign in / Sign up

Export Citation Format

Share Document